Marrone Bio Innovations (NASDAQ:MBII) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.
A number of other brokerages also recently weighed in on MBII. Jefferies Group reaffirmed a “hold” rating and set a $1.55 price target on shares of Marrone Bio Innovations in a report on Wednesday, March 21st. HC Wainwright set a $4.00 price target on shares of Marrone Bio Innovations and gave the stock a “buy” rating in a report on Thursday, December 21st. Finally, Zacks Investment Research downgraded shares of Marrone Bio Innovations from a “hold” rating to a “sell” rating in a report on Thursday, February 15th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of $2.18.
Shares of Marrone Bio Innovations stock opened at $3.25 on Friday. Marrone Bio Innovations has a 1-year low of $0.85 and a 1-year high of $3.39. The company has a quick ratio of 0.36, a current ratio of 0.69 and a debt-to-equity ratio of -1.14. The company has a market cap of $259.08, a PE ratio of -3.04 and a beta of -0.54.
Marrone Bio Innovations (NASDAQ:MBII) last issued its quarterly earnings results on Thursday, March 29th. The basic materials company reported ($0.24) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.26) by $0.02. The firm had revenue of $3.32 million for the quarter. research analysts forecast that Marrone Bio Innovations will post -0.14 earnings per share for the current year.
In related news, insider Ardsley Advisory Partners acquired 6,666,667 shares of the company’s stock in a transaction that occurred on Monday, February 5th. The stock was acquired at an average price of $0.75 per share, with a total value of $5,000,000.25. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. 2.80% of the stock is owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/07/valuengine-upgrades-marrone-bio-innovations-mbii-to-sell.html.
About Marrone Bio Innovations
Marrone Bio Innovations, Inc offers bio-based pest management and plant health products. The Company’s bio-based products include naturally occurring microorganisms, such as bacteria, fungi and plant extracts. It sells its products to crop protection market. Its four crop protection products include Regalia, Grandevo, Venerate and Majestene.
Receive News & Ratings for Marrone Bio Innovations Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marrone Bio Innovations and related companies with MarketBeat.com's FREE daily email newsletter.